Furthermore, patients with secondary resistance are accompanied by elevated IL-4 expression (Fig. 1D), therefore, we conclude that high levels of IL-4 lead to gastric cancer anti-PD-1 immunotherapy resistance. This evidence concerns the gene IL4 and gastric cancer.